Singapore, 17 March 2017 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that members of its senior management will present and participate at the BioPharma Asia Convention 2017, which will take place from 21-23 March 2017 at the Suntec Singapore Convention and Exhibition Centre.
Dr Carl Firth, Chief Executive Officer of ASLAN, will deliver the first keynote session on 23 March 2017 at 9:10am. Titled ‘From ideas to international success: A real breakthrough story brought to you by an Asian biotech company’, Dr Firth will speak about ASLAN’s journey in building itself as a quality Asian biotech.
Mr Yen Zhao Yi, ASLAN’s Finance and Business Development Analyst, will be conducting a session at the convention’s Biotech Bootcamp. To be held on 21 March 2017 at 9:00am, “Financing a cure: Getting your business plan and pitch book right for successful fundraising” will focus on how companies can best prepare for fundraising.
Into its 10th year, the BioPharma Asia Convention brings together leading biopharma organisations, biotech entrepreneurs and big pharma companies from across the region. More information on the Convention can be found at http://www.terrapinn.com/exhibition/bio-asia/index.stm.
Ends
Media contact
Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287
Email: ASLAN@spurwingcomms.com
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and breast cancer. ASLAN has several compounds in late stage development: varlitinib (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for biliary tract cancer; and ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer. www.aslanpharma.com
Dr Carl Firth, Chief Executive Officer of ASLAN, will deliver the first keynote session on 23 March 2017 at 9:10am. Titled ‘From ideas to international success: A real breakthrough story brought to you by an Asian biotech company’, Dr Firth will speak about ASLAN’s journey in building itself as a quality Asian biotech.
Mr Yen Zhao Yi, ASLAN’s Finance and Business Development Analyst, will be conducting a session at the convention’s Biotech Bootcamp. To be held on 21 March 2017 at 9:00am, “Financing a cure: Getting your business plan and pitch book right for successful fundraising” will focus on how companies can best prepare for fundraising.
Into its 10th year, the BioPharma Asia Convention brings together leading biopharma organisations, biotech entrepreneurs and big pharma companies from across the region. More information on the Convention can be found at http://www.terrapinn.com/exhibition/bio-asia/index.stm.
Ends
Media contact
Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287
Email: ASLAN@spurwingcomms.com
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and breast cancer. ASLAN has several compounds in late stage development: varlitinib (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for biliary tract cancer; and ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer. www.aslanpharma.com
